Recently, over-the-counter mild analgesic use during pregnancy has been suggested to influence the risk of reproductive disorders in the offspring. We examined the influence of maternal exposure to mild analgesics during pregnancy on the occurrence of cryptorchidism and hypospadia in their offspring.
Introduction
Congenital anomalies are a significant cause of stillbirth and infant mortality and are also important contributors to childhood morbidity . Although cryptorchidism (undescended testis) is one of the most common abnormalities in newborn boys worldwide, the aetiology in boys without chromosomal abnormalities is largely unknown (Pierik et al., 2005; Chacko and Barthold, 2009 ). Reproductive disorders, including cryptorchidism, hypospadia and poor semen quality are hypothesized to constitute a testicular dysgenesis syndrome, in which environmental and genetic factors play a role (Skakkebaek et al., 2001; Main et al., 2009) .
Use of medication, such as diethylstilbestrol and valproic acid therapy, during pregnancy increases the risk of congenital malformations, including cryptorchidism and hypospadia (Palmlund et al., 1993; Palmer et al., 2009; Jentink et al., 2010) . Recently, some evidence was presented that over-the-counter mild analgesic use may also increase the risk of cryptorchidism in the offspring (Kristensen et al., 2010) . In the Netherlands, 40% of the population uses over-the-counter self-medication such as acetaminophen (paracetamol) and non-steroidal anti-inflammatory drugs (NSAIDS) which are also used by pregnant women (Werler et al., 2005; Statistics Netherlands, 2011) .
Experimental rat models have shown that normal androgen action during a critical male programming window (gestational day 15.5-17.5) is crucial for the programming of the testis decent (Welsh et al., 2008) . Factors that diminish androgen action during that time may have detrimental consequences for male sexual differentiation (Skakkebaek et al., 2001) . Exposure of pregnant rats to phthalate esters during gestational days 15-17 resulted in hypospadia, cryptorchidism, testicular injury and nipple retention in male offspring, and this was attributed to reductions in testosterone synthesis (Foster, 2006) . A recent study by Kristensen et al. (2010) showed that paracetamol, even at low plasma concentrations such as 1 mM, is a potent inhibitor of testosterone production, reducing anogenital distance and testosterone production in rats. Furthermore, cyclooxygenase (COX) inhibitors, such as acetaminophen, ibuprofen and acetylsalicyclic acid have shown endocrine disrupting properties in rainbow trout, affecting steroid hormone synthesis (Gravel and Vijayan, 2006) . These experimental observations have found echos in human observational studies. As early as 1996, Berkowitz and Lapinski (1996) reported that the use of analgesics during pregnancy was a risk factor for cryptorchidism. A recent study by Jensen et al. (2010) among 47 400 live born children in the Danish National Birth Cohort showed that exposure to acetaminophen in both the first and second trimester increased the risk of cryptorchidism. Kristensen et al. (2010) were able to substantiate these observations among a different cohort of Danish pregnant women, and observed that combined use of acetaminophen with other analgesics further increased the risk of cryptorchidism. However, similar associations were not observed among Finnish mothers and their boys, possibly because this disorder is comparatively rare in Finland (Kristensen et al., 2010) . Further research is therefore urgently needed to corroborate or refute these findings.
The aim of this study was to investigate whether the use of mild analgesics during pregnancy by mothers was associated with an increased occurrence of cryptorchidism and/or hypospadia in their offspring. We conducted this study within the Generation R Study, a large prospective birth cohort study from early pregnancy onwards examining determinants of growth, development and health from fetal life until young adulthood (Jaddoe et al., 2010) .
Materials and Methods

Study design
The Generation R Study is a population-based prospective cohort study on growth, development and health from early fetal life until young adulthood in Rotterdam, the Netherlands. The study design has been described in detail previously (Jaddoe et al., 2010) . Briefly, all pregnant women who had an expected delivery date between April 2002 and January 2006 and who lived in the study area of Rotterdam were invited to participate. In total, 9778 pregnant women (response 61%) were enrolled in the study of which 8880 women were enrolled during pregnancy and another 898 were enrolled at the birth of their child. Extensive assessments were carried out during early pregnancy (gestational age , 18 weeks), midpregnancy (gestational age 18 -25) and late pregnancy (gestational age . 25 weeks), including physical examinations, questionnaires, interviews and biological samples. The study was approved by the Medical Ethics Committee at Erasmus University Medical Centre Rotterdam, The Netherlands (MEC 198.782/2001/31) . Written informed consent was obtained from all participants. The information required for this study was collected in three prenatal questionnaires completed during the first trimester (8116 women, 91% enrolment), the second trimester (7145 women, 80% enrolment) and the third trimester (6830 women, 77% enrolment). In total, 5177 partners completed a questionnaire during mid-pregnancy (82% of enrolment). The analyses were restricted to boys, and the presence of cryptorchidism and hypospadias was ascertained during 10 visits of children to the child health care centres (0-48 months). The flowchart of the study population is depicted in Fig. 1 .
Medication use
The three self-administered questionnaires assessed medication use during pregnancy and were sent out by post at gestational weeks 12, 20 and 30 with an average lag period to response of 2 weeks. The first questionnaire (sent out at 12 weeks of gestation) contained the following question 'Did you use any medication during the past 6 months?', whereby we explicitly asked for medication prescribed by a physician and medication bought over-the-counter, such as analgesics. This question was followed by a scheme in which mothers had to fill out the name of the medication, reason for use, age at the start of use, use during pregnancy, and if they stopped use when the pregnancy was known.
The second questionnaire (sent out at 20 weeks of gestation) contained the following question 'Did you use any medication during the past 2 months?' and the third questionnaire (sent out at 30 weeks of gestation) contained a similar question but focusing on the past 3 months.
We defined four time periods, namely, use during the periconception period (use before and during the first trimester of pregnancy), use during the first period (first 14 weeks of gestation), use during the second period (14 -22 weeks of gestation) and use during the third period (20-32 weeks of gestation). Women enrolled during early pregnancy (85% of the study population) completed the first questionnaire around 14 weeks of gestation (mean). Women who reported medication use before pregnancy and use during the first weeks of pregnancy until the pregnancy was known or thereafter were classified as periconception users, and women who used medications during the first weeks of pregnancy until the pregnancy was known or thereafter (strict selection from the group of periconception users) were classified as first period users (0-14 weeks of gestation). Women who were included after 20 weeks (15% of the study population) and 30 weeks (5% of the study population), were included in the second and/or third period analyses. Summarizing, for 2724 (85.6%) women, information on three time periods was available, for 443 (13.9%) women information on two time periods was available and for 17 (0.5%) women information on one time period was available. Use of mild analgesics in these four time periods was classified into use of paracetamol as over-the-counter medication, and use of all other painkillers, including NSAIDS and aspirin, on prescription or over-the-counter.
Reproductive disorders
The presence of cryptorchidism or hypospadia was assessed during routine screening assessments performed in child health care centres. Child health care centres are notified of live births within 2 days after Analgesics and reproductive disorders in offspring registration in the municipal birth register. Child health care centres invite all parents to participate in a national preventive child healthcare programme, free of charge. A total of 10 visits were planned at different ages, namely 0-6 months (five visits, 6591 children, 84% enrolment), 6 -12 months (one visit, 6414 children, 81% enrolment), 12 -18 months (two visits, 6088 children, 77% enrolment), 18 -24 months (one visit, 4478 children, 57% enrolment) and 24 -36 months (one visit, 5335 children, 68% enrolment). All visits included physical examinations, performed by trained physicians, including manipulation of the testes and inspection of the genitalia (Pierik et al., 2005) .
Testes deviating from the normal distal scrotal position were gently but firmly manipulated with warm hands, along the normal pathway of the descent, to their most distal position (de Muinck Keizer-Schrama, 1987) . Boys were diagnosed as cryptorchid if one or both testes were nonpalpable, or when they could not be manipulated to a stable position in the scrotum. Retractile testis can be manipulated to a stable scrotal position and were not considered cryptorchid, whereas cases of retentio testis manipulated to a scrotal position that returned to their abnormal position after release of pressure were classified as cryptorchid. The physicians reported whether the tests were performed, and reported the position of the testis after manipulation, as non-palpable, inguinal, ectopic, high scrotal, stable scrotal or non-assessable due to the presence of hydrocele. Hypospadias were also diagnosed and classified in the children. Trained physicians assessed whether hypospadia was present and which type it was (glandular or a more severe type), as described earlier by Pierik et al. (2002) .
When cryptorchidism or hypospadia was present at one of the 10 visits to the child health care centres, children were classified as a prevalent case. This resulted in a cumulative period prevalence of cryptorchidism and hypospadia over 30 months of follow up.
Potential confounders
For mothers, information on age, weight, education, country of origin, parity, underlying diseases, folic acid supplement use and general health was collected from the first questionnaire available. Smoking habits and alcohol use (no/until pregnancy was known/ and after pregnancy was known), infectious diseases during pregnancy (yes/no), fever during pregnancy (yes/no) and use of co-medication (yes/no) were collected from three prenatal questionnaires. The body mass index (BMI in kg/m 2 ) was calculated by weight divided by squared height. The occurrence of 'underlying disease' was defined as the presence of any disease from a structured list of 23 questions on specific diseases in the first questionnaire. General health was reclassified from five categories varying from excellent to poor into two categories comparing moderate and poor health to good with excellent health. Gestational age at birth and birthweight were obtained from medical records and hospital registries. Information on paternal characteristics, such as paternal age, BMI, education, country of origin, underlying diseases, smoking before pregnancy, alcohol use before pregnancy, occupational exposure to endocrine disruptors and pesticides, medication use before pregnancy and family history of congenital cryptorchidism, was collected from a mid-pregnancy questionnaire especially designed for partners of participating women.
Statistical analyses
Statistical analyses were performed using SPSS v17.0 (Chicago, IL, USA). Differences between categorical variables were tested with the Fisher's exact test, and differences between continuous variables were tested with one-way analysis of variance. We used logistic regression models to estimate the associations between several life-style related risk factors as well as mild analgesic use with cryptorchidism and hypospadia as dependent variables. Maternal and paternal age and BMI were investigated both as categorical and as continuous variables. Medication use was stratified per pregnancy period and evaluated for overall use of analgesics, use of paracetamol and use of other painkillers. The reference group only contained women who did not use any medication during pregnancy.
Potential confounders were selected based on evidence on relevant determinants of cryptorchidism and hypospadias in an earlier case-referent study conducted in the same area prior to the current birth cohort study (Pierik et al., 2004) . Both maternal and paternal factors were considered. First, we selected all reported potential confounders from both mother and father, including age, educational level, ethnicity, parity, BMI, smoking during pregnancy, alcohol use during pregnancy, underlying diseases, self-perceived general health, gestational age at birth, birthweight, occupational exposure to endocrine disruptors, occupational exposure to pesticides, medication use before and during pregnancy, and for women only folic acid supplement use, infectious disease during pregnancy and fever during pregnancy. Second, maternal age, maternal educational level, maternal BMI, maternal general health, maternal use of co-medication, maternal underlying diseases and maternal fever during pregnancy were included by default, while the other variables were retained in the multivariable model as confounders when they changed the odds ratio (OR) of mild analgesic use by more than 10% (Greenland and Mickey, 1989) . We tested the confounders during the period with the largest OR for mild analgesic use and applied the final set of confounders to the other periods. The final model for both cryptorchidism and hypospadia consisted only of the following confounders which were included by default: maternal age, maternal educational level, maternal BMI, maternal general health, maternal use of co-medication, maternal underlying diseases and maternal fever during pregnancy. Missing values in covariates were handled by multiple imputations (Markov chain Monte Carlo method) by generating five independent datasets for all analyses. Imputations were based on the relations between all covariates included in this study. The threshold for imputation was 30% of missing values, all covariates were imputed (Greenland and Finkle, 1995) . The pooled estimates from the multivariate models were used to construct the tables. We carried out a sensitivity analyses to assess the influence of the time enrolment on the effect estimates, comparing women included after 20 weeks of gestation with women enrolled before 20 weeks of gestation. The results from the multivariate analyses were used to estimate the population attributable fraction (PAF), expressing the proportion of the adverse health outcomes in the general population that is attributed to exposure to the risk factor of interest. The PAF is a function of both the relative risk and the proportion of exposed persons in the population (Last, 2001) . In this study ORs were used for the calculations of the PAF.
Results
The cumulative period prevalences of cryptorchidism and hypospadia in our study population were 2.1 and 0.7%, respectively. The baseline characteristics of the mothers are shown in Table I . The univariable and multivariable analyses of the lifestyle related and environmental risk factors are shown in Table II 
Continued
Analgesics and reproductive disorders in offspring analysis showed that after adjusting for use of mild analgesics during pregnancy, the effect estimates of life style and environmental factors were comparable. No other statistically significant differences were present among the groups. Tables III and IV present the results of the univariable and multivariable analyses on maternal use of mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadia. In total, 29.9% of the mothers in our study population used mild analgesics during pregnancy (956/3184). There was moderate agreement between mild analgesics users during the distinguished periods with k values varying between 0.23 and 0.40.
Among mothers with cryptorchid sons 33.8% (23 of 68) reported the use of mild analgesics during pregnancy, compared with 31.8% (7 of 22) of mothers with a boy with hypospadia, and 29.9% (926 of 3094) of mothers with healthy boys (adjusted OR 1.25; 95% CI 0.73 -2.13 and OR 0.98; 95% CI 0.38 -2.52, respectively). Mild analgesics primarily consisted of paracetamol (75%), followed by NSAIDS (13%) and other painkillers such as aspirin (12%).
A total of 484 (20.8%) and 252 (10.9%) mothers reported the use of mild analgesics during the periconception period and the first period, respectively. Use of mild analgesics in the periconception and first period was not associated with cryptorchidism or hypospadia (adjusted OR 0.89; 95% CI 0.42-1.88, OR 0.94; 95% CI 0.36 -2.46 for cryptorchidism, adjusted OR 1.36; 95% CI 0.47-3.94, OR 2.05; 95% CI 0.64 -6.58 for hypospadia).
In the second period (14 -22 weeks of gestation), containing 2864 women, 480 (16.8%) women reported the use of mild analgesics. Use during the second period in particular increased the risk of congenital cryptorchidism (adjusted OR 2.12; 95% CI 1.17 -3.83). The risk remained statistically significant for the individual compound paracetamol (adjusted OR 1.89; 95% CI 1.01-3.51). Associations with hypospadia were not observed.
In the third period (20-32 weeks of gestation), 363 out of 2709 (13.4%) women reported the use of mild analgesics. Maternal use of mild analgesics during the third period was not associated with congenital cryptorchidism or hypospadia (adjusted OR 1.56; 95% CI 0.78 -3.11, and OR 0.32; 95% CI 0.04-2.44, respectively).
The results of the sensitivity analyses indicated that there was no changes in the effect estimates when we restricted our analysis to women included before 20 weeks of gestation, however, due to the smaller sample size, the CIs widened.
The PAFs for the use of mild analgesics in the second and third trimester varied between 0.09 and 0.24 (95% CI 0.00 -0.29, and 0.04 -0.43, respectively).
Discussion
This large population-based prospective cohort study suggests that maternal exposure to mild analgesics during the second period (reflecting gestational weeks 14-22) in pregnancy is associated with an increased prevalence of cryptorchidism in the offspring, whereas no associations were observed during the first and third period of pregnancy. However, we must note that the current study has several limitations, most importantly the limited number of cases of cryptorchidism and hypospadia. We must also note that the definition of the different pregnancy periods was based on the average response time to the questionnaires, which will result in some lack of precision of the exact duration of the period. The distinguished pregnancy periods necessarily overlap, since standardized questions with fixed recall periods were used. Also, the users of analgesics in the different trimesters partly overlapped (k values 0.23 -0.40), which cannot exclude the possibility of a contribution of the previous trimester to the internal dose in the subsequent trimester. Despite these limitations, our findings suggest that intrauterine exposure to mild analgesics during pregnancy might increase the risk of cryptorchidism. Since the proportion of women using mild analgesics during pregnancy is high, the population impact may be substantial. corroborates findings from experimental rat studies and two recent observational studies. The strength of this study is the population-based approach with recruitment during the prenatal period which enabled us to assess, and adjust for, a large number of potential confounders. Since smoking, alcohol use and folic acid supplement use had many missing values, we used multiple imputation to handle missing values in our covariates. This reduces selection bias due to non-random missing values in the covariates. Another strength of the study lies in the frequent assessments that took place in the child health care centres, with assessments for cryptorchidism during five screening visits in the first 6 months. Spontaneous testicular descent occurs in up to 75% of cryptorchid testis during the first 3 months of life when reproductive hormone activity is high (Boisen et al., 2004) . The majority of children in our study visited the child health care centres in the first 6 months (89.4%), and subsequent visits made it possible to examine children who did not visit the child health care centre between 0 and 6 months, resulting in a cumulative period prevalence. We used questionnaires to assess the exposure to paracetamol and other mild analgesics. These analgesics are bought over-the-counter and therefore it was not possible to check information from pharmacies or general practitioners. We explicitly asked for use of painkillers which can be bought over-the-counter, and we observed that the number of women who reported use of mild analgesics in our study (29.9%) was comparable to Danish women reporting mild analgesic use in self-administered questionnaires in the study of Kristensen et al. (26.1 and 30.9%) . In our cohort, information on medication use was collected prior to the information on congenital malformations which were diagnosed after birth and, thus, recall bias is unlikely. Although misclassification may have occurred, we believe that this is most likely non-differential misclassification, leading to an underestimation of the observed effect estimates. An analysis restricted to women included before 20 weeks of gestation showed very similar results.
Some other limitations need to be addressed. Selection bias due to non-response would be present if the association of medication use with cryptorchidism or hypospadia differed between those with (n ¼ 3184) and those without (n ¼ 524) information on medication use. Although the general characteristics of women with data on medication use were slightly different from those without data on medication use, no difference in the occurrence of cryptorchidism and hypospadia was observed. Thus, selection bias due to non-response on medication use seems unlikely but cannot be excluded.
Another shortcoming of our design is the lack of information on the frequency and dose of painkiller use. Also, given the overlap between analgesics users in different periods during pregnancy, it is difficult to ascertain with certainty that mild analgesics use during one specific period is associated with an increased risk of cryptorchidism. However, agreement between the different periods during pregnancy was calculated by means of k values, which ranged between 0.23 and 0.40, indicating low agreement between these different pregnancy periods. we showed an association between use of mild analgesics during the second period in pregnancy and cryptorchidism. This study could increase the awareness for this important topic and stimulate researchers to set up larger studies. We calculated PAFs, ranging from 9 to 24%, which suggest, if causality could be established, that at best 24% of all cases of cryptorchidisms in our study population could be attributed to use of mild analgesics during pregnancy. This illustrates that for the majority of cryptorchidism cases other causes must be responsible, such as suboptimal maternal health, low birthweight and small-for-gestational age (Pierik et al., 2004; Foresta et al., 2008) .
Women who use painkillers during pregnancy may suffer from an underlying disorder which prompts medication use. The majority of women in our study used the analgesics for common pain such as headache and muscle ache. Confounding by indication may be present in mothers who regularly use painkillers, but adjustment for underlying diseases did not change the effect estimates by more than 10%. The analyses were adjusted for general health, use of co-medication, underlying diseases and fever during pregnancy as important proxy variables for indication to treat. None of the paternal risk factors in this study changed the association between maternal use of mild analgesics and cryptorchidism or hypospadia by more than 10%, thus paternal risk factors were not considered to be potential confounders. The study by Pierik et al. (2004) showed various paternal risk factors associated with the occurrence of cryptorchidism, however, in the current study these paternal risk factors did not confound the association between mild analgesic use of the mother during pregnancy and the occurrence of cryptorchidism. These paternal risk factors seem independent risk factors for cryptorchidism, but were not associated with the use of mild analgesics of the mother during pregnancy. However, residual confounding cannot be completely ruled out.
Cryptorchidism and hypospadia are among the most frequent congenital abnormalities in male births (Pierik et al., 2005) . Maternal life style factors and environmental exposures during pregnancy are suspected of interfering with normal testicular decent and possibly increase the risk of cryptorchidism (Chacko and Barthold, 2009; Toppari et al., 2010) . Experimental rat models have indicated that the testis decent from the intra-abdominal position into the scrotum takes place in two phases, a transdabdominal phase and an inguinoscrotal phase (Hutson et al., 1997; Welsh et al., 2008) . However, in humans, discussion exists over the exact time window in which the testis descent takes place. Hutson et al. (1997) described that the transdabdominal phase occurs between 8 and 14 weeks of gestation, whereas Foresta et al. (2008) defines this phase as between 10 and 23 weeks of gestation. Further research is needed to identify the exact critical time window in which testicular descent takes place.
Impairment of normal androgen action, through exposure to endocrine disrupting chemicals or medication in these crucial time windows, is associated with adverse reproductive developmental end-points in experimental animals (Toppari, 2008) . Recently, Kristensen et al. (2010) showed that paracetamol, even at low plasma concentrations of 1 mM, is a potent inhibitor of testosterone production, resulting in impaired masculinisation in rat models. These findings are also confirmed by two observational studies that showed similar associations between use of mild analgesics and cryptorchidism, in particular for the second trimester Kristensen et al., 2010) . We did not find an association between use of mild analgesics during pregnancy and hypospadia in the offspring, however we had very few cases (n ¼ 22) of hypospadia in our study. Therefore, we were unable to study with sufficient discriminatory power the hypothesized underlying mechanism of impairment of normal androgen action, resulting in abnormal sexual differentiation, for hypospadias, and the origin of hypospadia, genetic, endocrine or environmental, remains unclear (Kalfa et al., 2009) . Mild analgesics such as NSAIDs act by inhibiting COX 1 and 2. Acetaminophen (paracetamol) is thought to block the peroxidase function of COX enzymes (Aronoff et al., 2006) , although the precise mechanism by which the drug exerts its action is still uncertain (Anderson, 2008) . COX enzymes catalyse a key step of the synthesis of prostaglandins from arachidonic acid. It has been shown that the testosterone-dependent differentiation of the male reproductive tract requires the continuing synthesis of prostaglandins (Gupta and Bentlejewski, 1992) . Suppression of prostaglandin production by interfering with the arachidonic acid cascade at the level of release of arachidonic acid from cell membrane lipids or by inhibiting COX enzymes diminishes fetal androgen action and compromises male sexual differentiation (Gupta and Goldman, 1986) . Accordingly, Kristensen et al. demonstrated that acetaminophen is capable of suppressing fetal androgen synthesis in male rats exposed ex vivo to the drug during late fetal life. The day before birth, the male fetuses showed reduced anogenital distances, another sign of diminished androgen action (Kristensen et al., 2010) . In a subsequent paper, Kristensen et al. (2011) were able to pinpoint the suppression of prostaglandin synthesis by acetaminophen and other NSAIDs to the inhibition of COX enzymes. Importantly, the same authors revealed many other putative endocrine disrupting chemicals, including phthalates and other phenolic agents as possessing prostaglandin-inhibitory potential. In the light of these observations, it appears biologically plausible that not only NSAIDs, but also other endocrine disrupting chemicals, may contribute to increasing the risks of developing cryptorchidism by interfering with prostaglandin synthesis. It becomes necessary to address this possibility in further epidemiological studies.
In conclusion, we found an association between maternal use of mild analgesics, in particular paracetamol, during the second period in pregnancy (14-22 weeks of gestation) and congenital cryptorchidism. Since the number of women using mild analgesics during pregnancy is high ( 30-40%), further research is urgently needed to corroborate these findings, so that preventive measures, if needed, can be taken.
